Oruka Therapeutics Prices Upsized $700 Mln Offering To Advance Psoriasis Pipeline

Oruka Therapeutics priced an upsized $700.4 million underwritten public offering, materially strengthening its balance sheet. The financing supports two late-stage dermatology programs targeting ultra-infrequent dosing for chronic skin diseases. The news is positive for funding visibility and clinical execution, though the immediate market impact is likely limited to the stock.

Analysis

Oruka Therapeutics priced an upsized $700.4 million underwritten public offering, materially strengthening its balance sheet. The financing supports two late-stage dermatology programs targeting ultra-infrequent dosing for chronic skin diseases. The news is positive for funding visibility and clinical execution, though the immediate market impact is likely limited to the stock.